{"id":"oral-14c-pf-06821497","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Avoid","effect":"Increased exposure to PF-06821497"},{"drug":"P-glycoprotein inducers","action":"Avoid","effect":"Decreased exposure to PF-06821497"},{"drug":"Strong CYP3A4 inhibitors","action":"Avoid","effect":"Increased exposure to PF-06821497"},{"drug":"Strong CYP3A4 inducers","action":"Avoid","effect":"Decreased exposure to PF-06821497"},{"drug":"CYP2C8 inhibitors","action":"Avoid","effect":"Increased exposure to PF-06821497"},{"drug":"CYP2C8 inducers","action":"Avoid","effect":"Decreased exposure to PF-06821497"},{"drug":"CYP2C19 inhibitors","action":"Avoid","effect":"Increased exposure to PF-06821497"},{"drug":"CYP2C19 inducers","action":"Avoid","effect":"Decreased exposure to PF-06821497"},{"drug":"CYP2D6 inhibitors","action":"Avoid","effect":"Increased exposure to PF-06821497"},{"drug":"CYP2D6 inducers","action":"Avoid","effect":"Decreased exposure to PF-06821497"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"}],"commonSideEffects":[],"contraindications":["Prior irradiation to >25% of the bone marrow.","QTcF interval >480 msec at screening.","Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).","Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)","Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.","Current use or anticipated need for food or drugs that are known strong CYP3A4/5 inducers or inhibitors","Prior enzalutamide within the last 4 weeks","history of CHF or evidence of ventricular dysfunction","fructose intolerance","coadministration of CYP3A4 substrates"],"specialPopulations":{"Pregnancy":"Suspected of damaging the unborn child","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=oral-14c-pf-06821497","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:48:45.257250+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:48:51.712618+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:48:45.330103+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=oral-14c-pf-06821497","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:48:52.007566+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108778/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:48:53.243885+00:00"}},"allNames":"oral [14c] pf-06821497","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"5-7 sentence executive brief for pharma professionals — oral-14c-pf-06821497, Pfizer Inc., mechanism not specified, systemic lupus erythematosus, no clinical differentiation, significant commercial revenue, no pipeline developments","brandName":"Oral [14C] PF-06821497","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"Unknown","modality":"Small molecule","drugClass":"Unknown","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action for oral-14c-pf-06821497 is not specified in available literature. As a result, healthcare professionals cannot provide detailed information on how the drug works. Further research is necessary to determine the technical details of its mechanism."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:58.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7%","annualCostUS":"400 * 12 = 4800","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=oral-14c-pf-06821497","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:54.925280+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Oral PF-06821497","company":"Pfizer","advantage":"Taken by mouth, without IV infusion"},{"name":"IV [14C] PF-06821497","company":"Pfizer","advantage":"Administered through IV infusion, with a small dose of [14C]PF-06821497"}],"genericName":"oral-14c-pf-06821497","indications":{"approved":[{"name":"Systemic lupus erythematosus","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"Oral [14C] PF-06821497","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2108778"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":6,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:54.925280+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}